Delivery Order SPE2DB25D3504-SPE2DB25FVVNT
Award Date 7/16/25
Potential Completion Date 7/17/25
Potential Value $16K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $94,166.98 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on November 24, 2025. This non-competitive, firm fixed price delivery order is scheduled for completion by November 25, 2025, with performance to be fulfilled at the contractor's Conshohocken, Pennsylvania facility. Dupixent (dupilumab) is a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and other...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,981.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on October 29, 2025. This non-competitive delivery order, classified as firm fixed price, is set to be completed by October 30, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $25,144.81 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on June 16, 2025, with completion scheduled for June 17, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,467.88 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL quantity) on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency (DLA) awarded a $41,691.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitive award, which carries no set-aside designation, is scheduled for completion by August 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory and allergic conditions, including...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $14,525.26. This firm fixed-price delivery order, which is expected to be completed by August 4, 2025, was competitively awarded with no set-aside designation. The product will be delivered to the prime contractor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,857.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on November 20, 2025, with an ultimate completion date of November 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,548.66 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on December 8, 2025, with a completion date of December 9, 2025. This non-compete, firm fixed-price delivery order represents a single pharmaceutical procurement from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The drug will be distributed from AmerisourceBergen's headquarters location in Conshohocken,...